Phase 1 clinical trial for Hantavirus vaccines yields positive interim results

GOLDEN, Colo. — March 13, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the reporting of positive interim results from the Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS), using the PharmaJet Stratis® needle-free injection system.

Zika Virus vaccine shows significantly higher immune response with Needle-free delivery

GOLDEN, Colo. — Jan. 9, 2018 — PharmaJet, the maker of innovative, needle-free injection technology announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via needle and syringe.